Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE On the basis of the obtained results, in the atherosclerosis mice treated with the agomir of miR-9 and siRNA against OLR1, the p38-mitogen-activated protein kinase (p38MAPK) pathway was inhibited; levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol, tumor necrosis factor-α, interleukin-6, and vascular endothelial growth factor were reduced, but the high-density lipoprotein cholesterol level was increased, along with decreased vulnerable atherosclerotic plaque area and enhanced vascular remodeling. 31571264 2020
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Oxidized low-density lipoprotein (ox-LDL) leads to atherosclerosis via lectin-like oxidized lipoprotein receptor-1 (LOX-1), one of the major receptor for ox-LDL. 30871430 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis. 31336709 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Hexarelin decreased the aortic expressions of CD68 and LOX-1 which were elevated in the AS group. 31386895 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. 30819724 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE These observations provide clinical support to experimental studies implicating LOX -1 in atherosclerosis and its possible role as target for cardiovascular intervention. 30744454 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE Effect of oral magnesium sulfate administration on lectin-like oxidized low-density lipoprotein receptor-1 gene expression to prevent atherosclerosis in diabetic rat vessels. 30328289 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE We hereby provide an updated overview of role of LOX-1 in atherosclerosis and associated vascular diseases, with an aim to highlighting the potential of LOX-1 as a novel theranostic tool for cardiovascular disease prevention and treatment. 30381837 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE Many naturally occurring compounds have been shown to modulate LOX-1 expression and atherosclerosis. 29737246 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE We first selected LOX-1 as our target, which was reckoned as a new promising receptor for treating atherosclerosis. 29735887 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Recent results demonstrated that LOX-1, a receptor associated with obesity and atherosclerosis, is overexpressed in advanced and metastatic prostate cancer. 29107109 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE In a model of cellular transformation, the MCF10A ER-Src, inhibition of LOX-1 gene reduces NF-kB activation and the inflammatory and hypoxia pathways, suggesting a mechanistic connection between cellular transformation and atherosclerosis. 29462603 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE The lectin-like, oxidized low-density lipoprotein (ox-LDL) receptor-1 (LOX-1)/ox-LDL system contributes to atherosclerosis and may be involved in cartilage degeneration. 28348422 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE LOX-1: A potential target for therapy in atherosclerosis; an in vitro study. 28860004 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Previous studies have revealed that endothelial lectin‑like ox‑LDL receptor‑1 (LOX‑1) and long intergenic noncoding RNA p21 (lincRNA‑p21) may serve as therapeutic targets for atherosclerosis and associated cardiovascular disorders. 28983628 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Lectin-like oxLDL receptor-1 (LOX1) is one of the major contributors of oxLDL uptake and degradation in macrophages, which leads to foam cell formation and the development of atherosclerosis. 28941610 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 GeneticVariation disease BEFREE Proanthocyanidins are oligomers of catechins that exhibit potent antioxidative activity and inhibit binding of oxidized low-density lipoprotein (OxLDL) to the lectin-like oxidized LDL receptor (LOX-1), which is involved in the onset and development of arteriosclerosis. 29054360 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE DHA also contributes to the prevention of arteriosclerosis by regulating the expression of oxidized low density lipoprotein receptor 1, plasminogen activator inhibitor 1, thromboxane A2 receptor, and adhesion molecules such as vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, and intercellular adhesion molecule 1 in endothelial cells. 28619112 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE Literature data demonstrate a protective role of LOXIN in pathologies correlated with LOX-1 overexpression such as atherosclerosis and tumors. 28146073 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE Proanthocyanidin, an oligomer of catechin, is a natural antioxidant and a potent inhibitor of lectin-like oxidized LDL receptor-1, which is involved in the pathogenesis of arteriosclerosis. 28082039 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 Biomarker disease BEFREE MicroRNA let-7g alleviates atherosclerosis via the targeting of LOX-1 in vitro and in vivo. 28535009 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 GeneticVariation disease BEFREE The up-regulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), encoded by the OLR1 gene, plays a fundamental role in the pathogenesis of atherosclerosis. 26542080 2016
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 GeneticVariation disease BEFREE Both OLR1 and PCSK9 genes are associated with atherosclerosis, cardiovascular disease and ischemic stroke. 26666837 2015
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.100 AlteredExpression disease BEFREE OA could alleviate high fat diet induced atherosclerosis in quail and ox-LDL induced cytotoxicity in HUVECs; the potential mechanism involves modulation of LOX-1 activity, including inhibition of expression of NADPH oxidase subunits and increase of the expression of nrf2 and ho-1. 26510581 2015